Chain of Identity for Cell Therapies: Digital Traceability from Patient to Product and Back

Chain of identity represents the single most critical digital capability in autologous cell therapy operations. When a patient’s own cells are collected, shipped to a manufacturing facility, genetically engineered, expanded, and returned to that same patient for infusion, the unbroken digital thread linking every physical material to its originating patient constitutes the difference between a life-saving therapy and a potentially lethal medical error. Unlike conventional pharmaceutical manufacturing where a product mix-up results in a patient receiving the wrong drug, which is serious but often survivable, an autologous cell therapy mix-up means a patient receives living cells engineered from another person’s immune system, creating the risk of severe graft-versus-host disease, immune rejection, and death. This absolute intolerance for identity error places chain of identity systems in a category of criticality that has no parallel in pharmaceutical IT.

The challenge of maintaining chain of identity across the cell therapy workflow is compounded by the number and diversity of participants in the process. A single patient’s therapy may involve an ordering physician at the treatment center, an apheresis team at the collection site that may or may not be the treatment center, a courier service that transports the collected material, a receiving team at the manufacturing facility, multiple manufacturing operators across different shifts and process steps, quality control analysts testing the product, a logistics coordinator scheduling the return shipment, a second courier service for the return journey, and a clinical team at the treatment site that receives and administers the product. Each of these handoffs represents a point where identity must be positively verified and documented, and each involves different organizations, different IT systems, and different levels of digital maturity.

The regulatory expectations for chain of identity in cell therapy are unambiguous but the specific technical requirements for achieving compliant COI systems are still evolving. Both the FDA and EMA require that manufacturers demonstrate robust identity tracking throughout the product lifecycle, but neither agency prescribes specific technologies or system architectures. This regulatory flexibility places the burden on manufacturers to design, validate, and defend COI systems that demonstrably prevent mix-up errors, and it creates an opportunity for digital innovation that can differentiate manufacturers in their ability to scale operations while maintaining the absolute identity integrity that patient safety demands.

The Identity Imperative in Personalized Medicine

The chain of identity challenge in cell therapy is a direct consequence of the personalized nature of these medicines. Understanding why identity management is categorically different for personalized therapies compared to conventional pharmaceuticals provides the foundation for designing IT systems that address the true nature and magnitude of the risk.

Autologous vs. Allogeneic Identity Requirements

Autologous cell therapies, manufactured from a patient’s own cells, represent the most demanding identity management scenario because every unit of starting material, every intermediate, and every unit of finished product is unique to and intended for a single specific patient. There is no interchangeability, no pooling, and no possibility of using one patient’s product for another. The chain of identity must maintain an absolute, unbroken link between the patient’s clinical identity and every physical material associated with their therapy throughout the entire process. Allogeneic therapies, manufactured from donor cells for administration to multiple patients, have different but still substantial identity requirements. While the finished product is not patient-specific, the identity of the donor material must be tracked throughout manufacturing for traceability purposes, and the allocation of finished product doses to specific patients must be documented for post-administration follow-up. The chain of identity requirements for allogeneic therapies more closely resemble those for blood products, with established frameworks from transfusion medicine providing a starting point for system design.

The Consequence Asymmetry

In conventional pharmaceutical manufacturing, identity-related errors have a spectrum of consequences ranging from minor, such as receiving a different strength of the same medication, to serious, such as receiving a medication to which the patient is allergic. Quality systems, including good distribution practices and pharmacy verification procedures, provide multiple layers of defense against these errors. In autologous cell therapy, the consequence spectrum collapses to a single catastrophic outcome: immunological attack by foreign cells that the patient’s body recognizes as non-self. This consequence asymmetry means that the traditional pharmaceutical approach of defense-in-depth through multiple independent verification layers, while necessary, is insufficient. The COI system must be designed to make mix-up errors physically impossible through system-enforced controls, not merely improbable through procedural safeguards.

Chain of Identity vs. Chain of Custody

Chain of identity and chain of custody are related but distinct concepts that serve different purposes in cell therapy operations. Conflating them creates gaps in system design that can compromise patient safety.

Chain of Identity Defined

Chain of identity answers the question: is this material associated with the correct patient? It establishes and maintains the linkage between a physical material, whether starting material, manufacturing intermediate, or finished product, and the patient identity that the material belongs to. Chain of identity verification is performed by comparing the identity information associated with the physical material against the expected identity for the current workflow step. A positive identity verification confirms that the material in hand is the material expected for the patient currently being processed. Chain of identity is a forward-looking, preventive control that operates before an action is taken: verify identity, then proceed with the processing step.

Chain of Custody Defined

Chain of custody answers the question: who handled this material, when, where, and under what conditions? It documents the transfer of physical possession of materials between individuals, organizations, and locations. Chain of custody records capture the identity of the person or organization releasing the material, the identity of the person or organization receiving the material, the date, time, and location of the transfer, the condition of the material at the time of transfer, and any documentation that accompanies the material. Chain of custody is a retrospective, documentary control that creates the audit trail needed to investigate events after they occur: reconstruct the handling history to identify what happened and why.

Why Both Are Required

A robust cell therapy traceability system requires both chain of identity and chain of custody operating in concert. Chain of identity prevents mix-up errors by ensuring positive identification before each handling step. Chain of custody provides the investigative capability to reconstruct the complete handling history when questions arise about product integrity, to demonstrate regulatory compliance with material handling and storage requirements, and to identify root causes when deviations or quality events occur. The IT system must support both functions through integrated workflows that capture identity verification and custody transfer documentation as part of a single, seamless operator interaction at each handoff point.

Regulatory Landscape for COI

The regulatory requirements for chain of identity in cell therapy span multiple agencies and regulatory frameworks, each of which establishes expectations for identity tracking without prescribing specific technologies or system architectures.

FDA Requirements

The FDA’s requirements for cell therapy identity tracking derive from multiple regulatory sources. The Current Good Manufacturing Practice requirements under 21 CFR Parts 210 and 211 establish general requirements for material identification and traceability. The biological product regulations under 21 CFR Part 600 establish specific requirements for the identification and traceability of biological products. The FDA’s guidance documents for cell and gene therapy products establish expectations for donor and recipient identification, material tracking, and the prevention of mix-up errors. The FDA’s 2026 announcement on flexible approaches to CMC oversight for cell and gene therapies acknowledges the unique manufacturing challenges of these products while maintaining the expectation that identity tracking systems provide absolute protection against mix-up errors.

EMA and EU Requirements

The European regulatory framework for cell therapy identity tracking is established through the Advanced Therapy Medicinal Products regulation, the EU GMP Guide Part IV specific to ATMPs, and the EU Tissues and Cells Directives. The EMA’s guidelines establish requirements for a single European coding system for tissues and cells, traceability from donor to recipient and vice versa, and documentation of every step in the manufacturing and distribution process that affects the identity or traceability of the product. The EU regulatory framework places particular emphasis on the traceability requirements for tissues and cells that are used as starting materials for ATMPs, creating a dual regulatory layer where both the tissue and cell regulations and the ATMP regulations impose identity tracking requirements.

Emerging Standards

Industry organizations are developing standards that provide more specific technical guidance for COI implementation. The Standards Coordinating Body for Cell, Gene, and Regenerative Medicines is developing frameworks for interoperable identity tracking across the cell therapy supply chain. The International Society for Cell and Gene Therapy has published recommendations for labeling and identification of cell therapy products. And organizations such as BioPhorum are developing standardized approaches to cell therapy traceability that aim to create common frameworks for COI data exchange between organizations.

Digital COI Architecture

The architecture of a digital chain of identity system must balance several competing requirements: absolute reliability in identity verification, usability in challenging clinical and manufacturing environments, flexibility to accommodate diverse partner capabilities, and scalability to support commercial operations across global networks.

Centralized vs. Distributed Architecture

COI system architecture presents a fundamental design choice between centralized systems where all identity records and verification logic reside in a single platform, and distributed systems where identity records are maintained locally at each site with synchronization to a central repository. Centralized architectures provide the advantage of a single source of truth for identity records, eliminating the synchronization challenges and conflict resolution requirements of distributed systems. However, centralized architectures create a single point of failure where platform unavailability prevents identity verification at all sites, and they depend on reliable network connectivity that cannot be guaranteed at all clinical sites in all geographies. Distributed architectures provide resilience against network failures and platform outages by maintaining local identity records that enable verification to continue during connectivity interruptions. However, they introduce the complexity of data synchronization, conflict resolution, and the risk that identity records may be temporarily inconsistent across sites during synchronization delays.

The Hybrid Approach

Most commercial COI implementations adopt a hybrid architecture that combines the single-source-of-truth benefits of centralization with the resilience benefits of distribution. In this model, the central platform maintains the authoritative identity record for each patient therapy, including all identity verification events, custody transfers, and status updates. Local sites receive a cached copy of the identity record for each active therapy, enabling identity verification to proceed even during brief connectivity interruptions. Synchronization protocols ensure that local events are transmitted to the central platform when connectivity is restored, with conflict detection and resolution mechanisms that flag discrepancies for human review. The hybrid approach requires careful attention to the scenarios where connectivity loss could create identity verification gaps, with procedures that define how manufacturing and logistics operations proceed when the central platform is unreachable and how the identity record is reconciled when connectivity is restored.

Identification Technologies and Selection

The selection of identification technologies for cell therapy COI systems involves evaluating multiple technology options against the specific environmental, operational, and regulatory requirements of cell therapy manufacturing and logistics.

Barcode Technologies

Linear barcodes remain widely used in cell therapy operations due to their low cost, universal readability, and compatibility with existing laboratory and clinical equipment. However, their limited data capacity restricts the amount of identity information that can be encoded directly on the label, typically requiring a database lookup to retrieve the full identity record. Two-dimensional barcode formats including Data Matrix and QR codes provide substantially higher data capacity, enabling the encoding of patient identifiers, product codes, manufacturing lot numbers, and expiration information in a single symbol. Data Matrix codes are particularly prevalent in cell therapy applications due to their compact size, high data density, and error correction capabilities that enable reliable reading even when labels are partially damaged or obscured. The primary limitation of barcode technologies is their requirement for line-of-sight scanning, which means that every identity verification event requires an operator to physically scan the label, introducing a human action that could be omitted or performed incorrectly under time pressure.

RFID and NFC Technologies

Radio-frequency identification offers several advantages for cell therapy COI applications. RFID tags can be read without line-of-sight, enabling automated identity verification at transition points without requiring operator scanning. Tags can be read at greater distances and through packaging materials, simplifying logistics operations. Read-write capability allows tag data to be updated at each process step, creating a portable identity record that travels with the material. And anti-collision protocols enable simultaneous reading of multiple tags, supporting batch-level verification operations. However, RFID implementation in cell therapy environments faces several challenges. Standard RFID tags may not function reliably at cryogenic temperatures, requiring specialized cryogenic-compatible tags that add cost and may have reduced performance compared to standard tags. Metallic surfaces in laboratory equipment and storage containers can interfere with RF signals, requiring careful tag placement and reader positioning. The higher per-unit cost of RFID tags compared to barcode labels may be significant for operations processing thousands of patient batches annually. And the regulatory validation of RFID-based identity systems requires demonstration that tag reading is reliable across all environmental conditions encountered in the cell therapy workflow.

Biometric and Molecular Identification

Emerging identification approaches for cell therapy include biometric patient identification at the point of collection and administration, and molecular identification technologies that enable direct verification of patient identity against the cellular material itself. Biometric identification, using technologies such as fingerprint scanning, iris recognition, or facial recognition, provides a direct link between the physical patient and the therapy order that does not depend on secondary identifiers such as wristbands or medical record numbers. Molecular identification approaches, including short tandem repeat profiling or single nucleotide polymorphism analysis, enable definitive verification that cellular material matches the patient’s genomic identity. While molecular identification cannot provide the rapid, point-of-care verification needed at every handoff point, it serves as an orthogonal verification layer that can confirm identity at critical milestones such as manufacturing initiation and pre-administration verification.

Identity Management at Collection Sites

The collection site is where the chain of identity begins, and the procedures and systems deployed at collection are the foundation upon which the entire identity chain is built. Errors at collection are the most dangerous because they propagate through every subsequent step of the process.

Patient Identification at Collection

Patient identification at the point of collection must follow a multi-factor verification process that confirms the patient’s identity using at least two independent identifiers, such as full name and date of birth, verified against the therapy order and the patient’s medical record. The COI system must capture the patient identification event with the identifiers used, the identity of the operator performing the verification, the method of verification, and the timestamp. This initial identity verification event becomes the anchor point for the entire chain of identity, and any discrepancy detected at this stage must halt the collection process until the discrepancy is resolved.

Material Labeling and Registration

Following patient identification, the collected material must be labeled with unique identifiers that link it to the patient record in the COI system. Labeling must occur immediately after collection, before the material leaves the collection area, to minimize the window of time during which unlabeled material could be confused with material from other patients. The COI system must support the generation and printing of labels at the collection site, with encoded identifiers that are unique across the entire network of collection sites and manufacturing facilities. The label must remain legible and scannable through all subsequent handling, including cryopreservation, transport, and thawing, which requires label materials and adhesives that are validated for the environmental conditions the material will encounter.

Collection Site Technology Requirements

Collection sites present unique technology challenges because they range from major academic medical centers with sophisticated IT infrastructure to community hospitals with minimal digital capabilities. The COI system must provide a solution that works across this spectrum, from full integration with the site’s electronic health record system for sites that can support it, to a standalone mobile application that requires only a smartphone or tablet with cellular connectivity for sites with limited IT infrastructure. Regardless of the integration level, the collection site solution must enforce the same identity verification workflow and capture the same documentation at every site, ensuring that the quality of the identity record is independent of the site’s IT sophistication.

Manufacturing Identity Controls

Manufacturing facilities processing multiple patient batches simultaneously face the most complex identity management challenge in the cell therapy workflow. The IT systems must maintain absolute segregation of patient materials while enabling efficient manufacturing operations that maximize facility throughput.

Material Receipt and Incoming Verification

When patient material arrives at the manufacturing facility, the incoming verification process must confirm the identity of the material against the expected patient record, verify the condition of the material including temperature history from transport monitoring data, reconcile the physical material with the electronic chain of custody record from the collection site, and register the material in the facility’s local systems including LIMS and MES while maintaining the identity linkage established at collection. This incoming verification represents a critical transition point where identity tracking passes from the logistics domain to the manufacturing domain, and any discrepancy between the expected and received identity information must trigger a hold on manufacturing until the discrepancy is investigated and resolved.

In-Process Identity Controls

During manufacturing, the MES must enforce identity verification at every step where materials could potentially be confused. This includes verification before cell isolation procedures, before adding reagents or media to patient-specific cultures, before genetic modification steps where viral vectors or other modification agents are applied to patient cells, before transfers between processing vessels, before samples are withdrawn for in-process testing, and before final product harvest and formulation. In environments where multiple patient batches are processed simultaneously, the system must enforce spatial and temporal segregation rules that define which processing areas can contain which patient materials at any given time, with automated alerts when segregation rules are violated. The system must also prevent materials from being added to the wrong batch by verifying that the scanned material identity matches the active batch identity for the specific processing step being performed.

Label Reconciliation

Label management within the manufacturing facility requires strict reconciliation procedures to prevent the possibility of a mislabeled product leaving the facility. The COI system must track the issuance of every label generated for each patient batch, account for every label that is applied to containers, samples, or documentation, reconcile the number of labels issued against the number used, spoiled, and destroyed, and flag any label reconciliation discrepancies for investigation before the batch can proceed to the next process step. This label reconciliation is particularly important at the final labeling step where the finished product is labeled for shipment, as a labeling error at this stage would directly result in the wrong product being shipped to a patient.

Logistics and Transport Identity Tracking

The logistics phase of cell therapy delivery introduces identity tracking challenges that are unique to the transport environment, where materials pass through the custody of third-party courier services, cross international borders, and may spend days in transit under conditions that the manufacturer cannot directly control.

Shipment-Level Identity Management

Each shipment in the cell therapy logistics chain must carry identity documentation that enables verification at every handoff point. This documentation includes the patient identifier linked to the shipment, the contents description including container identifiers and quantities, the temperature monitoring device identifier, the required storage and handling conditions, the intended recipient and delivery destination, and the expected delivery window. The COI system must generate and transmit this documentation electronically to the receiving site before the shipment arrives, enabling the receiving site to verify the incoming shipment against the expected delivery. For international shipments, the identity documentation must be integrated with customs declarations and import permits, ensuring that the regulatory requirements for cross-border transport of biological materials do not create gaps in the identity chain.

Transit Monitoring and Alerting

During transit, the COI system must maintain continuous visibility into the location and condition of each patient’s material through GPS tracking devices embedded in shipping containers, temperature monitoring data transmitted wirelessly to the monitoring platform, and geofencing alerts that trigger when shipments deviate from expected routes or enter restricted zones. The monitoring platform must correlate transit data with the identity record, ensuring that any condition that could affect product integrity, such as a temperature excursion or an unexpected transit delay, is linked to the specific patient record and triggers appropriate evaluation and documentation.

Administration-Site Verification

The final identity verification before product administration to the patient represents the last opportunity to prevent a mix-up error and must therefore incorporate the most rigorous verification procedures in the entire chain of identity workflow.

Pre-Administration Identity Verification

Pre-administration verification must confirm the patient’s identity using the same multi-factor verification process used at collection, verify the product identity by scanning the product label and confirming it matches the patient record, verify the product condition including visual inspection and temperature verification, confirm that quality release has been completed and documented, and verify that the product is within its validated shelf life or viability window. The COI system must enforce these verification steps as mandatory prerequisites to administration, preventing the infusion process from proceeding until all verifications are complete and documented. The verification should involve at least two independent clinical personnel who each confirm the patient and product identity, creating a dual-verification layer at the most critical point in the process.

Administration Documentation

The administration event completes the chain of identity record, documenting the date, time, and location of administration, the identity of the clinical personnel who performed the administration, the identity of the personnel who performed the pre-administration verification, the condition of the product at the time of administration, and any observations during the administration procedure. This documentation closes the loop on the chain of identity, creating a complete record from patient identification at collection through product administration that can be reviewed for regulatory compliance, used for post-administration follow-up and pharmacovigilance, and referenced in the event of any adverse event investigation.

COI Platform Design Principles

The design of a commercial-grade COI platform must reflect several principles that emerge from the unique requirements and risks of cell therapy identity management.

Fail-Safe by Design

The COI platform must be designed so that any system failure defaults to a safe state. If the scanning system fails, manufacturing cannot proceed rather than proceeding without verification. If the database is unavailable, the system blocks operations rather than allowing operations without identity confirmation. If a network connection is lost, the system enters a degraded mode that still enforces local identity verification rather than allowing unverified operations. This fail-safe design philosophy means that COI system availability directly impacts manufacturing throughput, making platform reliability and availability a critical design requirement. The system must be architected for high availability with redundant components, automated failover, and recovery procedures that minimize downtime.

Usability Under Pressure

COI verification procedures are performed by operators working in cleanroom environments, by clinical staff managing acutely ill patients, and by logistics personnel handling time-sensitive shipments. The user interface must be designed for these environments, with large touch targets suitable for gloved hands, clear visual and auditory confirmation of successful verification, unambiguous error indication when verification fails, minimal text entry requirements, and workflows that guide the operator through the verification sequence without requiring memorization of complex procedures. The balance between security and usability is critical: a system that is so cumbersome that operators seek workarounds is less safe than a streamlined system that operators use consistently and correctly.

Auditability and Transparency

Every event captured by the COI platform must be stored in a tamper-evident audit trail that meets GxP data integrity requirements. The audit trail must record not only successful verification events but also failed verifications, verification timeouts, system errors, and any operator overrides or manual procedures invoked during system degradation. Regulatory inspectors must be able to reconstruct the complete identity history of any patient’s therapy from the audit trail, from collection through administration, including every person who verified identity, every system that participated in the verification, and every exception or deviation that occurred during the process.

Standards and Interoperability

The multi-organization nature of cell therapy operations makes interoperability between COI systems a critical requirement. A patient’s therapy may traverse COI systems operated by the collection site, the courier service, the manufacturing facility, the testing laboratory, and the treatment center, and the identity chain must remain unbroken across all of these system boundaries.

Emerging Industry Standards

The Standards Coordinating Body for Cell, Gene, and Regenerative Medicines is leading the development of interoperability standards for cell therapy COI systems. These standards address common data elements that must be exchanged between systems to maintain the identity chain, coding systems for patient identifiers, product identifiers, and process step identifiers that enable unambiguous identification across organizational boundaries, and communication protocols that define how identity data is transmitted between systems operated by different organizations. The adoption of ISBT 128, the international standard for coding and labeling of blood products, tissues, and cells, provides a foundation for cell therapy identity coding, with extensions being developed to accommodate the specific requirements of manufactured cell therapy products.

Platform Integration Approaches

Commercial COI platforms increasingly serve as integration hubs that connect the diverse systems involved in cell therapy operations. These platforms provide partner portals that enable clinical sites, courier services, and testing laboratories to interact with the COI system through web-based interfaces without requiring local system installation or integration. They offer API-based integration for partners with the technical capability to connect their own systems directly. And they provide mobile applications that enable field-based operations including collection site activities, courier handoffs, and bedside verification using smartphones or tablets with barcode scanning capabilities. The goal is to create a unified identity tracking experience across all participants in the cell therapy workflow, regardless of the IT sophistication of individual partner organizations.

The Future of Digital Chain of Identity

Chain of identity technology for cell therapies is evolving rapidly as the industry scales and as new technologies create opportunities for enhanced identity assurance.

Blockchain and Distributed Ledger Technologies

Blockchain technology offers potential advantages for cell therapy COI through its inherent properties of immutability, transparency, and distributed verification. A blockchain-based COI system would create a permanent, tamper-proof record of every identity verification event that is distributed across all participants in the therapy workflow, eliminating the possibility of retrospective alteration and providing all participants with real-time visibility into the identity chain status. Several pilot programs have explored blockchain-based COI for cell therapies, demonstrating technical feasibility but also highlighting challenges including transaction processing speed, data privacy requirements for patient-identifiable information, regulatory acceptance of distributed ledger technology for GxP records, and the governance structures needed to manage a shared ledger across multiple organizations with potentially competing interests.

AI-Enhanced Identity Verification

Artificial intelligence is beginning to enhance COI systems through capabilities such as anomaly detection that identifies unusual patterns in identity verification data that may indicate procedural errors or system manipulation, predictive alerting that anticipates identity verification challenges before they occur based on historical data and workflow patterns, and image-based verification that uses computer vision to verify label integrity, confirm that labels match expected formats, and detect potential tampering or degradation. These AI enhancements operate as additional verification layers that augment rather than replace the fundamental scanning and comparison operations that form the core of the COI system.

Toward Universal Interoperability

The ultimate vision for cell therapy COI is a globally interoperable identity tracking ecosystem where any collection site, manufacturing facility, or treatment center can participate in any therapy program through standardized identity data exchange. Achieving this vision requires convergence on common coding standards, common data exchange protocols, and common verification procedures across the industry. Progress toward this goal is being driven by industry consortia, regulatory harmonization efforts, and the commercial interests of COI platform providers who benefit from network effects as their platforms are adopted across the cell therapy ecosystem. The organizations that invest in robust, standards-compliant COI systems today will be positioned to participate in this emerging ecosystem, while those that rely on proprietary, non-interoperable solutions will face increasing integration costs as the industry converges on common standards.

Chain of identity is not merely a regulatory requirement or an IT system feature. It is the foundational safety system that makes personalized cell therapy possible at commercial scale. The digital thread that links a patient’s identity to their therapy at every step of the journey from collection through administration is the thread upon which that patient’s life depends. Organizations that recognize this imperative and invest accordingly in purpose-built, rigorously validated, and continuously improved COI systems will build the trust with regulators, clinicians, and patients that enables commercial success in personalized medicine. Those that treat COI as a checkbox compliance exercise will discover that the consequences of inadequate identity systems, whether measured in patient harm, regulatory action, or commercial failure, are orders of magnitude more severe than the investment required to get it right.